Healthpeak Properties, Inc. (DOC) Balance Sheet

The $1.2B increase in total assets over the past year was funded primarily by debt, as total liabilities rose from $10.9B to $12.2B, while equity stayed around $7.8B. This suggests the balance sheet is expanding through leverage rather than retained earnings, a trend that may pressure future financial flexibility. The modest decline in equity from $8.9B in Q1 2024 to $7.8B in Q2 2026 indicates that dividend distributions and negative AFFO are eroding book value, warranting close monitoring of capital allocation.

The steady decline in net property, plant, and equipment from $440.6M in Q2 2024 to $395.1M in Q2 2026 may reflect dispositions or depreciation outpacing capital additions, which could signal a shrinking asset base. The negative NOI in Q1 2026 (-$150.4M) and Q4 2025 (-$627.3M) is highly unusual and likely driven by one-time charges or reclassifications, but it raises questions about the stability of the income-producing portfolio. Investors should monitor whether these anomalies are temporary or indicate a broader deterioration in property performance.

The $1.2B increase in total debt over the period aligns with the Physicians Realty Trust acquisition, but the debt-to-equity ratio remains moderate compared to peers like Ventas (1.05) and Welltower (0.49). However, the sharp rise in cash from $101.8M in Q1 2024 to $1.6B in Q2 2026 suggests that a portion of the debt may be held as liquidity, possibly for future development or to manage near-term maturities. The maturity profile and interest rate exposure are not disclosed in the provided data, but the elevated cash balance may indicate a precautionary stance amid uncertain capital markets.

With FFO of $346.6M in Q2 2026, the lack of equity growth suggests that dividend payments and possibly asset impairments are consuming the majority of internally generated capital. The negative AFFO of -$394.8M in Q2 2026, as highlighted in the cash flow analysis, indicates that recurring capital expenditures exceed cash earnings, forcing the company to rely on external financing or asset sales to fund growth. This dynamic may limit the company's ability to expand its equity base organically, making it more dependent on debt or equity issuance for future investments.

The substantial increase in cash suggests that the company may have drawn on its credit facility or issued debt to build a liquidity buffer, possibly in anticipation of capital expenditures or to address upcoming debt maturities. While this improves short-term liquidity, it also increases interest expense and leverage, which could weigh on future earnings. The negative NOI in recent quarters and the thin net margin of 2.53% indicate that the company's operating performance is not yet generating sufficient cash flow to cover its obligations, making the cash reserve critical for maintaining financial stability.

The volatility in FFO per share suggests that the portfolio's income stream is not stable, possibly due to lease expirations or variable performance in the life science segment. The company's cluster strategy in high-barrier markets like Boston and San Francisco may provide some protection, but the softness in lab leasing and slow capital raising for H2 2025, as noted in recent context, could lead to higher vacancy and lower rental growth. Investors should monitor the lease expiration schedule and the progress of the development pipeline, as delays or cost overruns could further pressure cash flows and leverage metrics.